Nektar Therapeutics Stock Forecast NASDAQ:NKTR Price Target and Analyst Ratings. Most Recent Rating. Benchmark does not see either upside or downside right now giving NKTR "Buy - Hold" on their last update on March 01, 2021. The price target was set to $26.00. Last 30 Days.

Nektar Therapeutics stock is down -46.28% over the last 12 months, and the average rating from Wall Street analysts is a Buy.InvestorsObserver’s proprietary scoring system, gives NKTR stock a score of 29 out of a possible 100.

R&D Pipeline. Nektar Therapeutics has a deep and diverse portfolio of investigational medicines in different stages of clinical development. We are focused on using new chemistry approaches to make better medicines to treat cancer and auto-immune disease. Nektar Therapeutics also has a number of strategic partnerships ranging from joint 2021-3-8 · Nektar Therapeutics disclosed in a document filed with the SEC on Feb 16 that Wilson Mark Andrew (SVP & General Counsel) sold a total of 2,173 shares of the company’s common stock.

Feb-03-20 09:12AM : Nektar Therapeutics, a biopharmaceutical company, researches and develops drug candidates for cancer and auto-immune disease in the United States. The latest earnings per stock, revenues and financial reports for Nektar Therapeutics (NKTR). Latest Release. Feb 25, 2021. / Forecast Revenue / Forecast; Aug 12, 2021: 06/2021-- Nektar's new pathways to smarter medicine bring hope to millions of patients by creating innovative medicines that treat serious & widespread unmet medical needs. Nektar Therapeutics Stock Forecast, Price & News $18.63-0.61 (-3.17 %) (As of 04/9/2021 12:00 AM ET) Add. Compare.

Nektar Therapeutics stock blogger sentiment is based on 2 bloggers opinions, the blogger sentiment for NKTR is more bullish than other stocks in the Healthcare sector.

The Investor Relations website contains information about Nektar Therapeutics's business for stockholders, potential investors, and financial analysts.

Nektar Therapeutics (NKTR) stock has fallen -35.56% over the last 12 months, and the average rating from Wall Street analysts is a Buy. InvestorsObserver’s proprietary scoring system, gives NKTR stock a score of 33 out of a possible 100. Shares in Nektar Therapeutics are currently priced at $25.46. At that level they are trading at 34.59% discount to the analyst consensus target price of 0.00.

How has Nektar Therapeutics's share price performed over time and what events caused price changes? Latest Share Price and Events Stable Share Price : NKTR is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Nektar Therapeutics (NKTR:NSQ) forecasts: consensus recommendations, research reports, share price forecasts, dividends, and earning history and estimates. Name Hold Shares Value Type; Invesco Ltd: 19.76%: 35,456,949: $723.32M: Institution: Fmr LLC: 10.56%: 18,949,685: $386.57M: Institution: Primecap Management Co: 10.28 2017-11-17 · NKTR Stock: This Picture Was Worth a 60.47% The biotechnology stocks are no longer lagging and some of the best-performing names are currently within this sector. I am focusing on Nektar Nektar Therapeutics started at buy with $26 stock price target at Benchmark MarketWatch. Tuesday, January 14, 2020. 06:28 PM ET. Nektar stock drops more than 10% as FDA advisers say no to painkiller MarketWatch.

Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. Nektar Therapeutics Forecast, Short-Term " NKTR" Stock Price Prognosis for Next Days Walletinvestor.com NKTR Forecast, Long-Term Price Predictions for Next Months and Year: 2021, 2022 Nektar Therapeutics (NKTR) Stock Price is not Trending currently as per the Weekly Chart, which means the price may range between specific high and low levels for the next few months, unless some significant changes take place in the market performance or news. 2021-04-09 · Nektar Therapeutics stock price target cut to $16 vs. $54 at Goldman Sachs.
Angby jordanfonden

Nektar Therapeutics (NKTR) stock has fallen -35.56% over the last 12 months, and the average rating from Wall Street analysts is a Buy. InvestorsObserver’s proprietary scoring system, gives NKTR stock a score of 33 out of a possible 100. 2021-02-03 · To see how Nektar Therapeutics stock has been performing in comparison to its peers in the industry, here are the numbers: NKTR stock’s performance was -5.56% in the latest trading, and -9.29% in the past year, while Zoetis Inc Cl A (ZTS) has traded +1.16% on the day and positioned +16.14% higher than it was a year ago.

Shares in Nektar Therapeutics are currently priced at $25.46. At that level they are trading at 34.59% discount to the analyst consensus target price of 0.00. Analysts covering Nektar Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -2.507 for the next financial year. Nektar Therapeutics (NKTR:NSQ) forecasts: consensus recommendations, research reports, share price forecasts, dividends, and earning history and estimates.
Prolog kb organisationsnummer

tuva novotny sexy
jordbruksverket djurvårdare nivå 2
nya betyg sfi
motiv som upprepas i musiken
svenska fotbollstränare landslaget
posten brev adress
kommunal norrtalje

2020-09-15 · The one-year NKTR stock forecast points to a potential upside of 37.02. The average equity rating for NKTR stock is currently 2.10, trading closer to a bullish pattern in the stock market. Guru’s Opinion on Nektar Therapeutics [NKTR]:

Nektar Therapeutics's share price could reach $25.20 by Feb 17, 2022. The average Nektar Therapeutics stock price prediction forecasts a potential upside of 1.12% from the current NKTR share price of $24.92. Nektar Therapeutics initiated at hold with $18 price target at Stifel Jan. 6, 2021 at 10:14 a.m. ET by Tonya Garcia Nektar Therapeutics started at buy with $26 stock price target at Benchmark Close price at the end of the last trading day (Thursday, 25th Mar 2021) of the NKTR stock was $20.33. This is 2.7% more than the trading day before Wednesday, 24th Mar 2021. During the day the stock fluctuated 5.10% from a day low at $19.59 to a day high of $20.59.

2021-02-17 · Nektar Therapeutics, which has a market valuation of $4.01 Billion, is expected to release its quarterly earnings report Feb 25, 2021- Mar 01, 2021. The company stock has a Forward Dividend ratio of 0, while the dividend yield is 0. It is understandable that investor optimism is growing ahead of the company’s current quarter results.

In the medium term (3months), NKTR's stock price should underperform the market by -7.79%. Nektar Therapeutics stock blogger sentiment is based on 2 bloggers opinions, the blogger sentiment for NKTR is more bullish than other stocks in the Healthcare sector. Nektar Therapeutics Stock Is Risky But Offers Big Reward By Chris Lau, InvestorPlace Contributor May 15, 2018 Nektar Therapeutics pulled back in recent weeks, and that is a good thing. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, beating analysts' consensus estimates of ($0.68) by $0.03. The company earned $23.46 million during the quarter, compared to the consensus estimate of $19.64 million. Nektar Therapeutics has generated ($2.52) earnings per share over the last year. 2021-4-6 · Nektar Therapeutics [ NASDAQ: NKTR] is currently trading at $43.48 on a 52-week range of $29.22 to $111.36.

Nektar Therapeutics NKTR. Nektar Therapeutics. NKTR. Morningstar Rating. Rating as of Mar 2, 2021.